Compare Companies
| Field | 🇺🇸 Varda Space Industries | 🇺🇸 Axiom Space |
|---|---|---|
| Type | private | private |
| Country | 🇺🇸 United States | 🇺🇸 United States |
| Founded | 2020 | 2016 |
| CEO | Will Bruey | Michael Suffredini |
| Mkt Cap / Valuation | Undisclosed post-Series C (July 2025) | ~$2.5B+ (PitchBook estimate post-Feb 2026 round) |
| Employees | ~150 | ~800+ |
| Sector | In-space manufacturing | Commercial Space Stations |
| Last raise / Last filing | $187M (2025-07) | $350M (2026-02-12) |
| Top risks | Pre-revenue: each mission requires significant upfront capex; commercial pharmaceutical customers must validate space-manufactured drug substances.; Regulatory risk: FDA/EMA approval pathways for space-manufactured drugs are undefined. | ISS deorbit planned ~2030 compresses the market window for ISS-attached modules; SpaceX Crew Dragon is the sole current transport option — pricing and availability risk |
| Next catalyst | W-Series 2 and subsequent missions scaling pharmaceutical production (2026) | Axiom Mission 5 (Ax-5) — next private astronaut mission to the ISS (NET 2027-01) |
Maximum 4 companies. Pass slugs in the ids query parameter, comma-separated. Try SpaceX vs Blue Origin vs Rocket Lab vs Firefly.